In children with leukaemia, aggressive chemotherapy with prolonged neutropenia is associated with an increased incidence of systemic fungal infections.1 A syndrome of hepatic candidosis due to fungal microabscesses has been increasingly reported in neutropenic children. There are now several lipid suspensions of amphotericin under evaluation which offer a novel therapeutic approach to invasive fungal disease. They are expensive, and direct comparison clinical trials are required to determine whether they should replace conventional amphotericin as the initial treatment of all fungal sepsis. In hepatic candidosis the poor results with conventional treatment argue strongly in favour of using liposomal amphotericin B as a first line treatment.
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